KCNA1 (Potassium Voltage-Gated Channel Subfamily A Member 1) encodes the Kv1.1 voltage-gated potassium channel, a critical regulator of neuronal excitability. First characterized in 1994 as the cause of episodic ataxia type 1 (EA1), KCNA1 has since been implicated in epilepsy, neuromyotonia, neuropathic pain, and more recently in neurodegenerative diseases including Alzheimer's and Parkinson's disease[1].
| Property | Value |
|---|---|
| Gene Symbol | KCNA1 |
| Full Name | Potassium Voltage-Gated Channel Subfamily A Member 1 |
| Chromosomal Location | 12p13.32 |
| NCBI Gene ID | 3736 |
| OMIM | 176260 |
| Ensembl ID | ENSG00000111245 |
| UniProt | P09488 |
| Protein Name | Kv1.1 (Potassium voltage-gated channel subfamily A member 1) |
KCNA1 encodes the Kv1.1 α-subunit, a membrane protein consisting of:
The functional channel is a tetramer of four α-subunits, which can form homomeric (Kv1.1 only) or heteromeric channels with other Kv1 family members (Kv1.2, Kv1.3, etc.)[2].
Kv1.1 exhibits characteristic voltage-dependent gating:
The channel activates rapidly (1-2 ms) and can undergo both fast C-type and slow N-type inactivation depending on subunit composition and accessory proteins[3].
In the central nervous system, Kv1.1 is strategically positioned:
| Region | Function |
|---|---|
| Axonal Initial Segment (AIS) | Regulates action potential initiation |
| Nodes of Ranvier | Ensures saltatory conduction |
| Presynaptic Terminals | Modulates neurotransmitter release |
| Dendrites | Controls dendritic excitability |
| Somatic Membrane | Regulates neuronal firing patterns |
The precise localization is mediated by interaction with anchoring proteins including PSD-93 (postsynaptic density protein 93), SAP97, and Pick1 (protein interacting with C kinase 1)[4].
Kv1.1 channels are fundamental to proper neuronal signaling:
Kv1.1 modulates neurotransmitter release at presynaptic terminals:
In myelinated axons, Kv1.1 at the nodes of Ranvier:
Emerging evidence links Kv1.1 dysfunction to Alzheimer's disease pathogenesis:
Mechanisms:
Evidence:
Kv1.1 channels play complex roles in dopaminergic neuron survival:
Dopaminergic neuron vulnerability:
Potential mechanisms:
KCNA1 mutations are a well-established cause of epileptic phenotypes:
Kv1.1 dysfunction may contribute to axonal degeneration:
KCNA1 mutations cause EA1, characterized by:
Over 40 pathogenic mutations have been identified, most affecting channel gating kinetics[10].
Autoimmune attack on Kv1.1 causes:
Autoantibodies against Kv1.1 can be detected in patient serum[11].
Kv1.1 channels in sensory neurons contribute to pain signaling:
Kv1.1 channels are attractive drug targets for several conditions:
| Condition | Therapeutic Approach | Status |
|---|---|---|
| Epilepsy | Kv1.1 openers | Preclinical |
| Neuropathic pain | Selective Kv1.1 modulators | Research |
| Neuromyotonia | Immunosuppression | Clinical |
| EA1 | 4-aminopyridine | FDA approved |
Many venom peptides selectively target Kv1.1:
KCNA1 is highly expressed in:
| Cell Type | Expression Level | Function |
|---|---|---|
| Excitatory neurons | Moderate | Action potential regulation |
| Inhibitory interneurons | High | Network inhibition |
| Sensory neurons | High | Pain signaling |
| Motor neurons | Moderate | Axonal conduction |
Over 100 pathogenic KCNA1 variants have been identified:
Glasscock E, et al. Kv1.1 channelopathy: from mice to humans. Ann Neurol. 2002. ↩︎
Adelman JP, et al. SK channels and neuronal excitability. J Physiol. 2002. ↩︎
Imbrici P, et al. Kv1 channelopathies caused by KCNA1 mutations. Brain. 2007. ↩︎
Sheng J, et al. Kv1.1 regulates dendritic excitability and synaptic integration. Nat Commun. 2017. ↩︎
Ferrer G, et al. Axonal Kv1.1 channels and node of Ranvier function. J Neurosci Res. 2019. ↩︎
Chen L, et al. Dysregulation of Kv1.1 channels in Alzheimer's disease. J Neurosci. 2018. ↩︎
Husen K, et al. Kv1.1 channels in Parkinson's disease models. Neurobiol Dis. 2022. ↩︎
Jowett W, et al. KCNA1 mutations and epileptic encephalopathies. Epilepsia. 2008. ↩︎
Martinez D, et al. Voltage-gated potassium channels in neurodegenerative diseases. Nat Rev Neurosci. 2019. ↩︎
Giese KP, et al. Kv1.1 mutation and episodic ataxia type 1. Hum Mutat. 2018. ↩︎
Mueller GM, et al. Autoimmune Kv1.1 channel encephalitis. Ann Neurol. 2010. ↩︎
Yang Y, et al. Targeting Kv1.1 channels for neuropathic pain treatment. Pharmacol Rev. 2021. ↩︎
Köhler R, et al. K+ channel modulators in epilepsy therapy. Nat Rev Neurol. 2016. ↩︎